# Benitec Biopharma Inc.: financial statements, quarterly

BNTC · Nasdaq · CIK 1808898 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/bntc.md) · [Financials](/companies/bntc/financials.md) · [Filings](/companies/bntc/filings.md) · [Insiders](/companies/bntc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bntc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001193125-24-258672.md) | [0.0](/filings/0001193125-25-026631.md) | [0.0](/filings/0001193125-25-119383.md) | [0.0 d](/filings/0001193125-24-226968.md) | [0.0](/filings/0001193125-25-283274.md) | [0.0](/filings/0001193125-26-047737.md) | [0.0](/filings/0001193125-26-222885.md) | not reported | [0.0](/filings/0001193125-25-283274.md) | [0.0](/filings/0001193125-26-047737.md) | [0.0](/filings/0001193125-26-222885.md) | not reported |
| Research and development | $m | [4.4](/filings/0001193125-24-258672.md) | [5.1](/filings/0001193125-25-026631.md) | [2.6](/filings/0001193125-25-119383.md) | [3.5 d](/filings/0001193125-26-117604.md) | [3.6](/filings/0001193125-26-117604.md) | [5.4](/filings/0001193125-26-047737.md) | [6.5](/filings/0001193125-26-222885.md) | [2.9](/filings/0001193125-26-117604.md) | [3.4](/filings/0001193125-25-283274.md) | [5.8](/filings/0001193125-26-047737.md) | [6.3](/filings/0001193125-26-222885.md) | [7.9 d](/filings/0001193125-26-390570.md) |
| Operating income | $m | [(5.9)](/filings/0001193125-24-258672.md) | [(6.9)](/filings/0001193125-25-026631.md) | [(4.1)](/filings/0001193125-25-119383.md) | [(5.5) d](/filings/0001193125-26-117604.md) | [(5.8)](/filings/0001193125-26-117604.md) | [(10.8)](/filings/0001193125-26-047737.md) | [(15.3)](/filings/0001193125-26-222885.md) | [(9.8)](/filings/0001193125-26-117604.md) | [(9.8)](/filings/0001193125-25-283274.md) | [(13.4)](/filings/0001193125-26-047737.md) | [(13.6)](/filings/0001193125-26-222885.md) | [(14.4) d](/filings/0001193125-26-390570.md) |
| Net income | $m | [(6.0)](/filings/0001193125-25-119383.md) | [(6.8)](/filings/0001193125-25-119383.md) | [(4.3)](/filings/0001193125-25-119383.md) | [(4.7) d](/filings/0001193125-26-117604.md) | [(5.1)](/filings/0001193125-26-222885.md) | [(9.6)](/filings/0001193125-26-222885.md) | [(14.5)](/filings/0001193125-26-222885.md) | [(8.8)](/filings/0001193125-26-117604.md) | [(9.0)](/filings/0001193125-26-222885.md) | [(11.8)](/filings/0001193125-26-222885.md) | [(11.9)](/filings/0001193125-26-222885.md) | [(12.8) d](/filings/0001193125-26-390570.md) |
| Diluted EPS | $ per share | [(3.05)](/filings/0001193125-24-258672.md) | [(2.64)](/filings/0001193125-25-026631.md) | [(0.23)](/filings/0001193125-25-119383.md) | not reported | [(0.18)](/filings/0001193125-26-117604.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.38)](/filings/0001193125-26-222885.md) | [(0.21)](/filings/0001193125-26-117604.md) | [(0.22)](/filings/0001193125-25-283274.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.24)](/filings/0001193125-26-222885.md) | not reported |
| Basic EPS | $ per share | [(3.05)](/filings/0001193125-24-258672.md) | [(2.64)](/filings/0001193125-25-026631.md) | [(0.23)](/filings/0001193125-25-119383.md) | not reported | [(0.18)](/filings/0001193125-26-117604.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.38)](/filings/0001193125-26-222885.md) | [(0.21)](/filings/0001193125-26-117604.md) | [(0.22)](/filings/0001193125-25-283274.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.24)](/filings/0001193125-26-222885.md) | not reported |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.9](/filings/0001193125-23-275377.md) | [20.4](/filings/0001193125-24-032940.md) | [14.1](/filings/0001193125-24-136727.md) | [50.9](/filings/0001193125-26-117604.md) | [67.8](/filings/0001193125-24-258672.md) | [78.3](/filings/0001193125-25-026631.md) | [104](/filings/0001193125-25-119383.md) | [97.7](/filings/0001193125-26-390570.md) | [94.5](/filings/0001193125-25-283274.md) | [189](/filings/0001193125-26-047737.md) | [185](/filings/0001193125-26-222885.md) | [180](/filings/0001193125-26-390570.md) |
| Current assets | $m | [26.4](/filings/0001193125-23-275377.md) | [20.8](/filings/0001193125-24-032940.md) | [14.4](/filings/0001193125-24-136727.md) | [51.7](/filings/0001193125-26-117604.md) | [68.3](/filings/0001193125-24-258672.md) | [78.7](/filings/0001193125-25-026631.md) | [104](/filings/0001193125-25-119383.md) | [98.5](/filings/0001193125-26-390570.md) | [95.1](/filings/0001193125-25-283274.md) | [190](/filings/0001193125-26-047737.md) | [186](/filings/0001193125-26-222885.md) | [182](/filings/0001193125-26-390570.md) |
| Total assets | $m | [27.1](/filings/0001193125-23-275377.md) | [21.4](/filings/0001193125-24-032940.md) | [15.0](/filings/0001193125-24-136727.md) | [52.2](/filings/0001193125-26-117604.md) | [68.8](/filings/0001193125-24-258672.md) | [79.1](/filings/0001193125-25-026631.md) | [105](/filings/0001193125-25-119383.md) | [99.6](/filings/0001193125-26-390570.md) | [96.0](/filings/0001193125-25-283274.md) | [191](/filings/0001193125-26-047737.md) | [187](/filings/0001193125-26-222885.md) | [183](/filings/0001193125-26-390570.md) |
| Current liabilities | $m | [4.5](/filings/0001193125-23-275377.md) | [5.7](/filings/0001193125-24-032940.md) | [3.4](/filings/0001193125-24-136727.md) | [4.9](/filings/0001193125-26-117604.md) | [4.6](/filings/0001193125-24-258672.md) | [3.1](/filings/0001193125-25-026631.md) | [7.0](/filings/0001193125-25-119383.md) | [1.8](/filings/0001193125-26-390570.md) | [2.0](/filings/0001193125-25-283274.md) | [2.8](/filings/0001193125-26-047737.md) | [3.3](/filings/0001193125-26-222885.md) | [5.3](/filings/0001193125-26-390570.md) |
| Total liabilities | $m | [4.7](/filings/0001193125-23-275377.md) | [5.9](/filings/0001193125-24-032940.md) | [3.5](/filings/0001193125-24-136727.md) | [5.0](/filings/0001193125-26-117604.md) | [4.6](/filings/0001193125-24-258672.md) | [3.1](/filings/0001193125-25-026631.md) | [7.6](/filings/0001193125-25-119383.md) | [2.3](/filings/0001193125-26-390570.md) | [2.4](/filings/0001193125-25-283274.md) | [3.3](/filings/0001193125-26-047737.md) | [3.7](/filings/0001193125-26-222885.md) | [5.6](/filings/0001193125-26-390570.md) |
| Shareholders' equity | $m | [22.3](/filings/0001193125-25-119383.md) | [15.5](/filings/0001193125-25-119383.md) | [11.5](/filings/0001193125-25-119383.md) | [47.2](/filings/0001193125-26-390570.md) | [64.2](/filings/0001193125-26-222885.md) | [75.9](/filings/0001193125-26-222885.md) | [97.6](/filings/0001193125-26-222885.md) | [97.3](/filings/0001193125-26-390570.md) | [93.6](/filings/0001193125-26-222885.md) | [187](/filings/0001193125-26-222885.md) | [183](/filings/0001193125-26-222885.md) | [177](/filings/0001193125-26-390570.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,577)](/filings/0001193125-24-258672.md) | [(5,365) d](/filings/0001193125-25-026631.md) | [(6,168) d](/filings/0001193125-25-119383.md) | [(3,293) d](/filings/0001193125-26-117604.md) | [(4,586)](/filings/0001193125-25-283274.md) | [(7,703) d](/filings/0001193125-26-047737.md) | [(3,086) d](/filings/0001193125-26-222885.md) | [(8,213) d](/filings/0001193125-26-390570.md) | [(3,351)](/filings/0001193125-25-283274.md) | [(3,776) d](/filings/0001193125-26-047737.md) | [(4,452) d](/filings/0001193125-26-222885.md) | [(4,939) d](/filings/0001193125-26-390570.md) |
| Capital expenditure | $k | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-117604.md) | not reported | not reported | [6.0 d](/filings/0001193125-26-222885.md) | [0.0 d](/filings/0001193125-26-390570.md) | not reported | not reported | [15.0 d](/filings/0001193125-26-222885.md) | [79.0 d](/filings/0001193125-26-390570.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.6](/filings/0001193125-24-032940.md) | [1.6](/filings/0001193125-24-136727.md) | [2.2](/filings/0001193125-24-258672.md) | [2.6](/filings/0001193125-25-026631.md) | [18.3](/filings/0001193125-25-119383.md) | [27.9](/filings/0001193125-26-117604.md) | [37.3](/filings/0001193125-26-047737.md) | [38.6](/filings/0001193125-26-222885.md) | [41.2](/filings/0001193125-26-117604.md) | [41.5](/filings/0001193125-25-283274.md) | [46.0](/filings/0001193125-26-047737.md) | [49.4](/filings/0001193125-26-222885.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,882,726 at 2026-09-04, from the cover of the [10-K filed 2026-09-14](/filings/0001193125-26-390570.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.